Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Talis Biomedical Corp
Healthcare
P/NCAV
0.25x
Ticker
TLIS
Exchange
NASDAQ
Country
United States
Close
9.01 $
Mkt Cap
16.0M $
EV
-72.0M $
NCAV Burn Rate
41.2%
Current Ratio
10.6
Debt/Equity
0.0
EV/REV
-14.96x
EV/EBIT
0.6x
EV/FCF
0.7x
Dilution
3.2% p.A
Total Net Income
-445.0M $
Cheapness
95.0%
Talis Biomedical Corporation is engaged in transforming diagnostic testing by developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions at the point of care. The Company is engaged in developing the Talis One system, a cloud-enabled molecular diagnostic platform. The Talis One system consists of compact instrument, single-use test cartridges and software that is designed to support a central cloud database, which work together and are designed to provide central laboratory levels of accuracy and be operated by an untrained user. It is also focused on developing Talis One assay kits for respiratory infections, and infections related to women-s health and sexually transmitted infections (STIs). It is also developing influenza A and influenza B tests to be included as part of a respiratory panel with its COVID-19 assay (Respiratory Panel), as well as exploring adding a respiratory syncytial virus (RSV) test.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average